Overview

Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases

Status:
Unknown status

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

This project is aim to explore non-increased-intracranial-pressure symptomatic brain metastases of NSCLC, and if the OS of secondary brain radiotherapy after recurrence with Erlotinib is better than Erlotinib with concurrent brain radiotherapy. Treatment group are treated with Erlotinib until brain tumor progression, then gave brain radiotherapy, and continued to take Erlotinib till extracranial lesions progression. Control group are Erlotinib with concurrent brain radiotherapy, and continued to take Erlotinib after radiotherapy until recurrence or termination for other reasons.

Phase:

Phase 2

Details

Lead Sponsor:

Wu Jieping Medical Foundation

Collaborators:

Changhai Hospital
Fudan University
Longhua Hospital
RenJi Hospital
Shanghai Armed Police Hospital
Shanghai Changzheng Hospital
Shanghai Chest Hospital
Shanghai Pulmonary Hospital, Shanghai, China
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Treatments:

Erlotinib Hydrochloride